BRIEF-FDA Hologic Removes Biozorb 3D Bioabsorbable Markers Due To Risk For Patient ComplicationsDec 18 (Reuters) - Hologic Inc HOLX.O:
FDA: HOLOGIC REMOVES BIOZORB 3D BIOABSORBABLE MARKERS DUE TO RISK FOR PATIENT COMPLICATIONS
FDA: THERE HAVE BEEN 252 REPORTED INJURIES RELATED TO HOLOGIC'S BIOZORB 3D BIOABSORBABLE MARKERS
FDA: IDENTIFIED HOLOGIC'S RECALL AS MOST SERIOUS TYPE; RECALL INVOLVES REMOVING DEVICES FROM WHERE THEY ARE USED/SOLD
Source text: [ID:]
Further company coverage: HOLX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments